Fig. 5From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Meaningful change in ABC-CFXS subscales in the ≥ 90% methylation group. Percentage of patients who experienced meaningful changes from baseline in ABC-CFXS subscale scores, defined as a change of ≥ 3 for SA, ≥ 9 for Irr, or ≥ 5 for SU/L. The data represent results from the patients who had ≥ 90% methylation of the promoter region of the FMR1 geneBack to article page